Celgene Corp. (CELG)

Index: Nasdaq 100
0.17%
$0.24
$144.02
20:10 22/09/17
$144.02
20:10 22/09/17
DAILY VARIATION
0.17%
$0.24
VOLUME
1,985,149
DATA
52 Week High
$144.24
52 Week Low
$97.63
Shares Issued
782.35m
Market Cap
$112,677.82m
RiskGrade
94
Beta
0.63
MENU

Celgene Corp. Overview

Celgene engages in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases in the United States. It operates in two segments: Human Pharmaceuticals and Stem Cell Therapies.

Intraday Chart

Historic Charts

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 28.3% 53.7%
ROCE 42.1%
Latest F'cast
P/E 55.9 1,940.4
PEG 2.1 0.1
Pr/Revenue 10.1 8.4
Pr/Book 17.0
Latest F'cast
Revenue 22.1% 1.3%
PBT 17.2% n/a
EPS 27.2% 4.1%
DPS n/a 0.0%

Key Fundamentals

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2012-12-31 5,506.70 1,681.50 169.00¢ 23.2 1.4 17% n/a 0.0%
2013-12-31 6,362.30 1,665.40 175.00¢ 48.3 13.6 4% n/a 0.0%
2014-12-31 7,563.80 2,327.40 249.00¢ 44.9 1.1 42% n/a 0.0%
2015-12-31 9,161.10 2,023.50 202.00¢ 59.3 -3.1 -19% n/a 0.0%
2016-12-31 11,184.60 2,372.50 257.00¢ 45.0 1.7 27% n/a 0.0%

Forecast

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2017-12-31 13,266.95 7,122.92 731.59c 1,940.4 10.5 185% 0.00c 0.0%
2018-12-31 15,539.16 8,521.97 894.12c 1,587.0 71.4 22% 0.00c 0.0%

Regulatory News

No results found

Newspaper Links

No results found